Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Michigan Institute of Urology, P.C.
179
mi
from 43215
Troy, MI
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Michigan Institute of Urology, P.C.
179
mi
from 43215
Troy, MI
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Delaware Valley Urology, LLC Burlington
428
mi
from 43215
Mount Laurel, NJ
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Delaware Valley Urology, LLC Burlington
428
mi
from 43215
Mount Laurel, NJ
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Delaware Valley Urology, LLC
427
mi
from 43215
Voorhees, NJ
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Delaware Valley Urology, LLC
427
mi
from 43215
Voorhees, NJ
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Montefiore Medical Center
485
mi
from 43215
The Bronx, NY
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Montefiore Medical Center
485
mi
from 43215
The Bronx, NY
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Urologic Consultants of SE PA
416
mi
from 43215
Bala-Cynwyd, PA
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Urologic Consultants of SE PA
416
mi
from 43215
Bala-Cynwyd, PA
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Ilumina Clinical Associates
208
mi
from 43215
Indiana, PA
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Ilumina Clinical Associates
208
mi
from 43215
Indiana, PA
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Southern Interior Medical Research Inc.
1888
mi
from 43215
Kelowna,
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Southern Interior Medical Research Inc.
1888
mi
from 43215
Kelowna,
Click here to add this to my saved trials
Preventing Health Damaging Behaviors in Male and Female Army Recruits
Preventing Health Damaging Behaviors in Male and Female Army Recruits
Status: Enrolling
Updated:  8/24/2017
Fort Jackson Advance Individual Training Units
437
mi
from 43215
Columbia, SC
Preventing Health Damaging Behaviors in Male and Female Army Recruits
Preventing Health Damaging Behaviors in Male and Female Army Recruits
Status: Enrolling
Updated: 8/24/2017
Fort Jackson Advance Individual Training Units
437
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
City of Hope National Medical Center
1955
mi
from 43215
Duarte, CA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
City of Hope National Medical Center
1955
mi
from 43215
Duarte, CA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of California
1951
mi
from 43215
San Diego, CA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of California
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Stanford Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Stanford Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Florida College of Medicine (Shands)
714
mi
from 43215
Gainesville, FL
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Florida College of Medicine (Shands)
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
The Johns Hopkins SKCCC
345
mi
from 43215
Baltimore, MD
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
The Johns Hopkins SKCCC
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
DFCI/Brigham & Women's Hospital
643
mi
from 43215
Boston, MA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
DFCI/Brigham & Women's Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Michigan Medical Center
161
mi
from 43215
Ann Arbor, MI
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Michigan Medical Center
161
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Univ of Nebraska Med Ctr
682
mi
from 43215
Omaha, NE
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Univ of Nebraska Med Ctr
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Hackensack University Medical Center
476
mi
from 43215
Hackensack, NJ
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Hackensack University Medical Center
476
mi
from 43215
Hackensack, NJ
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Duke University Medical Center (peds)
354
mi
from 43215
Durham, NC
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Duke University Medical Center (peds)
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University Hospitals of Cleveland/Case Western
129
mi
from 43215
Cleveland, OH
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University Hospitals of Cleveland/Case Western
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Oregon Health and Sciences University
2026
mi
from 43215
Portland, OR
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Oregon Health and Sciences University
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Pennsylvania Cancer Center
414
mi
from 43215
Philadelphia, PA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Pennsylvania Cancer Center
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Texas, MD Anderson CRC
995
mi
from 43215
Houston, TX
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Texas, MD Anderson CRC
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Texas Transplant Institute
1138
mi
from 43215
San Antonio, TX
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Texas Transplant Institute
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Washington University/ Barnes-Jewish Hospital
398
mi
from 43215
Saint Louis, MO
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Washington University/ Barnes-Jewish Hospital
398
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation
Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation
Status: Enrolling
Updated:  8/24/2017
CUNY
442
mi
from 43215
New York, NY
Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation
Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation
Status: Enrolling
Updated: 8/24/2017
CUNY
442
mi
from 43215
New York, NY
Click here to add this to my saved trials
Targeting Platelets in Chronic HIV Infection
Targeting Platelets in Chronic HIV Infection
Status: Enrolling
Updated:  8/28/2017
Icahn School of Medicine at Mount Sinai
mi
from 43215
New York, NY
Targeting Platelets in Chronic HIV Infection
Targeting Platelets in Chronic HIV Infection
Status: Enrolling
Updated: 8/28/2017
Icahn School of Medicine at Mount Sinai
mi
from 43215
New York, NY
Click here to add this to my saved trials
Osteopathic Otitis Media Research Study
Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry
Status: Enrolling
Updated:  8/28/2017
University of New England College of Osteopathic Medicine
691
mi
from 43215
Biddeford, ME
Osteopathic Otitis Media Research Study
Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry
Status: Enrolling
Updated: 8/28/2017
University of New England College of Osteopathic Medicine
691
mi
from 43215
Biddeford, ME
Click here to add this to my saved trials
Osteopathic Otitis Media Research Study
Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry
Status: Enrolling
Updated:  8/28/2017
West Virginia School of Osteopathic Medicine
203
mi
from 43215
Lewisburg, WV
Osteopathic Otitis Media Research Study
Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry
Status: Enrolling
Updated: 8/28/2017
West Virginia School of Osteopathic Medicine
203
mi
from 43215
Lewisburg, WV
Click here to add this to my saved trials
Stool Microbiome, Pathogens, and Infectious Agents Among Olympic and Elite Athletes
TRMC-Bio "Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes"
Status: Enrolling
Updated:  8/28/2017
The Mayo Clinic
559
mi
from 43215
Rochester, MN
Stool Microbiome, Pathogens, and Infectious Agents Among Olympic and Elite Athletes
TRMC-Bio "Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes"
Status: Enrolling
Updated: 8/28/2017
The Mayo Clinic
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
1953
mi
from 43215
Anaheim, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
1953
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
2034
mi
from 43215
Carmichael, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
2034
mi
from 43215
Carmichael, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
2125
mi
from 43215
Fair Oaks, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
2125
mi
from 43215
Fair Oaks, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
2040
mi
from 43215
Sacramento, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
2040
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
1948
mi
from 43215
San Diego, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
1948
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
941
mi
from 43215
Boynton Beach, FL
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
941
mi
from 43215
Boynton Beach, FL
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
166
mi
from 43215
Indianapolis, IN
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
205
mi
from 43215
South Bend, IN
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
205
mi
from 43215
South Bend, IN
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
203
mi
from 43215
Portage, MI
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
203
mi
from 43215
Portage, MI
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
481
mi
from 43215
New York, NY
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
353
mi
from 43215
Chapel Hill, NC
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
307
mi
from 43215
Winston-Salem, NC
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
307
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
752
mi
from 43215
Tulsa, OK
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
752
mi
from 43215
Tulsa, OK
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
2026
mi
from 43215
Portland, OR
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
501
mi
from 43215
Memphis, TN
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
501
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
842
mi
from 43215
Saint Petersburg, FL
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
842
mi
from 43215
Saint Petersburg, FL
Click here to add this to my saved trials
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  8/29/2017
Melinta Investigational Site
555
mi
from 43215
Montgomery, AL
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 8/29/2017
Melinta Investigational Site
555
mi
from 43215
Montgomery, AL
Click here to add this to my saved trials